On April 1, 2026, Gabriel M.I. Mecklenburg, Director at Hinge Health (HNGE +3.18%), executed the sale of 50,000 Class A Common Stock shares for a total consideration of approximately $1.92 million, according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 50,000 |
| Transaction value | $1.9 million |
| Post-transaction shares (direct) | 0 |
| Post-transaction value (direct ownership) | ~$0 |
Transaction value based on SEC Form 4 weighted average purchase price ($38.46); post-transaction value based on April 1, 2026 market close ($38.49).
Key questions
- What is the derivative context for this sale?
The 50,000 Class A shares sold originated from the conversion of derivative securities, with the conversion occurring immediately prior to sale, aligning with common liquidity practices among equity holders with substantial vested options. - How does this transaction affect Mecklenburg's ownership in Hinge Health?
The sale reduced Mecklenburg's direct Class A Common Stock holdings to zero, but he continues to hold 3,268,813 Class B Common Stock shares (direct and indirect), which are fully convertible to Class A shares, supporting ongoing beneficial ownership. - Is this transaction part of a routine plan or discretionary action?
This transaction is part of a Rule 10b5-1 trading plan adopted by Mecklenburg on Dec. 1, 2025. - What is the context for transaction pricing relative to market levels?
The weighted average sale price of around $38.46 per share was in line with the April 1, 2026 market close of $38.49, suggesting no price concession for liquidity and reflecting normal market execution for volume at this scale.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-04-01) | $38.46 |
| Market capitalization | $3.07 billion |
| Revenue (TTM) | $587.86 million |
| Net income (TTM) | -$528.26 million |
* 1-year performance is calculated using April 1st, 2026 as the reference date.
Company snapshot
- Delivers digital healthcare solutions for musculoskeletal conditions, including joint and muscle health, acute injury, chronic pain, and post-surgical rehabilitation.
- Operates a software-driven platform that provides care management and support services for musculoskeletal conditions.
Hinge Health, Inc. is a healthcare technology company specializing in digital musculoskeletal care, leveraging a scalable software platform to address complex joint and muscle conditions.
What this transaction means for investors
Hinge Health stock has been on a rollercoaster of late. Over the last 12 months, shares soared by as much as 80%, before pulling back. Overall, shares have advanced by 23% over the last year. However, they have declined by 15% year to date, driven by broader market weakness.
The company, which operates in the health technology industry, reported solid fourth-quarter results in February 2026. Revenue increased by 46% year-over-year to $171 million, while free cash flow was $62 million, a 65% year-over-year increase. As a growth stock, Hinge remains focused on expanding its customer base and revenue. Total customers increased 25% to more than 2,800.
Turning to valuation, Hinge is looking more attractive, as its price-to-sales (P/S) ratio declines as revenue grows. For example, Hinge’s current P/S ratio stands at 5.4x, down from more than 10x in September 2025.
For growth-oriented investors interested in the health technology sector, Hinge Health is a stock to keep an eye on.
